BioCentury | Mar 12, 2012
Company News

Illumina, GlaxoSmithKline genomics news

...of the patent, plus damages. GSK gained the '023 patent through its 2008 acquisition of Genelabs Technologies Inc....
BioCentury | Mar 5, 2012
Product Development

Dynamic duo

...Inc. (now part of Roche ), Idenix Pharmaceuticals Inc. , Human Genome Sciences Inc. , Genelabs Technologies Inc....
...the time, Genelabs' lead program was a preclinical NS5A inhibitor. Masow said the collaboration with Genelabs...
BioCentury | Jan 11, 2010
Company News

Illumina, GlaxoSmithKline genomics news

...is marketed for DNA sequencing. GlaxoSmithKline gained the '023 patent through its 2008 acquisition of Genelabs Technologies Inc....
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...the PNAS article will be suitable for repurposing for HCV." Concurrent with its acquisition of Genelabs Technologies Inc....
...doi:10.1038/scibx.2010.3 Published online Jan. 7, 2010 Companies and Institutions Mentioned Debiopharm S.A. , Lausanne, Switzerland Genelabs Technologies Inc....
BioCentury | Aug 17, 2009
Company News

Novavax management update

...Business: Infectious Hired: Frederick Driscoll as VP and CFO, formerly CFO, president and CEO of Genelabs Technologies Inc. WIR...
BioCentury | Aug 10, 2009
Company News

NovaBay management update

...Infectious Hired: Roy Wu as SVP of business development, formerly VP of business development at Genelabs Technologies Inc. WIR...
BioCentury | May 4, 2009
Product Development

Palm needs Alms

...other large pharmas that have shown interest in NS5B inhibitors. Through its January acquisition of Genelabs Technologies Inc....
...that was in preclinical development. GL59728 is partnered with Novartis under a 2006 deal with Genelabs...
BioCentury | Jan 12, 2009
Company News

Genelabs, GlaxoSmithKline deal

...GlaxoSmithKline completed its previously announced tender offer for Genelabs, acquiring about 39.3 million shares (89%) at...
...remaining shares at the same price through a short-form merger (see BioCentury, Nov. 3, 2008). Genelabs Technologies Inc....
BioCentury | Jan 5, 2009
Company News

Genelabs, GlaxoSmithKline deal

...Genelabs. At Dec. 29, there were 36.4 million shares tendered (see BioCentury, Nov. 3, 2008). Genelabs Technologies Inc....
BioCentury | Dec 22, 2008
Company News

Genelabs, GlaxoSmithKline deal

...Genelabs. At Dec. 12, there were 35.1 million shares (79%) tendered (see BioCentury, Nov. 3). Genelabs Technologies Inc....
Items per page:
1 - 10 of 254
BioCentury | Mar 12, 2012
Company News

Illumina, GlaxoSmithKline genomics news

...of the patent, plus damages. GSK gained the '023 patent through its 2008 acquisition of Genelabs Technologies Inc....
BioCentury | Mar 5, 2012
Product Development

Dynamic duo

...Inc. (now part of Roche ), Idenix Pharmaceuticals Inc. , Human Genome Sciences Inc. , Genelabs Technologies Inc....
...the time, Genelabs' lead program was a preclinical NS5A inhibitor. Masow said the collaboration with Genelabs...
BioCentury | Jan 11, 2010
Company News

Illumina, GlaxoSmithKline genomics news

...is marketed for DNA sequencing. GlaxoSmithKline gained the '023 patent through its 2008 acquisition of Genelabs Technologies Inc....
BioCentury | Jan 7, 2010
Targets & Mechanisms

HCV cache: the list

...the PNAS article will be suitable for repurposing for HCV." Concurrent with its acquisition of Genelabs Technologies Inc....
...doi:10.1038/scibx.2010.3 Published online Jan. 7, 2010 Companies and Institutions Mentioned Debiopharm S.A. , Lausanne, Switzerland Genelabs Technologies Inc....
BioCentury | Aug 17, 2009
Company News

Novavax management update

...Business: Infectious Hired: Frederick Driscoll as VP and CFO, formerly CFO, president and CEO of Genelabs Technologies Inc. WIR...
BioCentury | Aug 10, 2009
Company News

NovaBay management update

...Infectious Hired: Roy Wu as SVP of business development, formerly VP of business development at Genelabs Technologies Inc. WIR...
BioCentury | May 4, 2009
Product Development

Palm needs Alms

...other large pharmas that have shown interest in NS5B inhibitors. Through its January acquisition of Genelabs Technologies Inc....
...that was in preclinical development. GL59728 is partnered with Novartis under a 2006 deal with Genelabs...
BioCentury | Jan 12, 2009
Company News

Genelabs, GlaxoSmithKline deal

...GlaxoSmithKline completed its previously announced tender offer for Genelabs, acquiring about 39.3 million shares (89%) at...
...remaining shares at the same price through a short-form merger (see BioCentury, Nov. 3, 2008). Genelabs Technologies Inc....
BioCentury | Jan 5, 2009
Company News

Genelabs, GlaxoSmithKline deal

...Genelabs. At Dec. 29, there were 36.4 million shares tendered (see BioCentury, Nov. 3, 2008). Genelabs Technologies Inc....
BioCentury | Dec 22, 2008
Company News

Genelabs, GlaxoSmithKline deal

...Genelabs. At Dec. 12, there were 35.1 million shares (79%) tendered (see BioCentury, Nov. 3). Genelabs Technologies Inc....
Items per page:
1 - 10 of 254